EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in,Preclinical Models ( ated We continue to make good progres...)

EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in,Preclinical Models

ated, "We continue to make good progress on our tubulin inhibitor program. The results of these studies will help us to further identify a lead molecule for evaluation in additional tumor models. ENMD-1420 and multiple compounds of a similar class are licensed exclusively from Celgene Corporation for development in oncology. These compounds have proven to be potent inhibitors of tumor growth and have both antiproliferative and antiangiogenic activities. We continue to evaluate ENMD-1420 and related compounds with the goal of identifying a lead molecule within the next twelve months."

To view the poster presentation, visit Scientific Presentations under the Therapeutic Pathways section of the Company's web site at www.entremed.com.

About Tubulin Inhibitors

Tubulins are the proteins that form microtubules, which are key components of the cellular cytoskeleton (structural network). Microtubules are necessary for cell division (mitosis), cell structure, transport, signaling and motility. Given their primary role in cell division, microtubules have been an important target for anticancer drugs -- often referred to as tubulin inhibitors or microtubule targeting agents. These compounds bind to tubulin protein, either in the monomer form or polymerized in microtubules, and prevent cancer cell proliferation by interfering with the microtubule dynamics required for cell division. This interference blocks the cell cycle sequence, leading to cell death (apoptosis).

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) (2-methoxyestradiol or 2ME2), the Company's lead drug candidate, is currently in Phase 2 clinical trials for cancer, as well as in preclinical development for rheumatoid arthritis. MKC-1, an oral cell cycle regulator, is in Phase 2 studies for cancer. ENMD-1
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
4. EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers
5. EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting
6. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
9. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
10. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
11. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis

Post Your Comments:

(Date:5/24/2013)... -- In accordance with Rule 17.1 and Rule 2.9 of ... States Exchange Act, Echo Pharma Acquisition Limited ("Royalty Pharma") today ... ELN). Background On 2 May 2013, ... the entire of the issued and to be issued share ... On 20 May 2013, Royalty Pharma announced the ...

(Date:5/23/2013)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ) ... Life Science Firm of the Year by the Tech Council ... at the TCM,s 25 th Annual Tech Awards Celebration ... Awards Celebration recognizes the leaders and innovators in the technology ... and the surrounding regions. "We are deeply ...

(Date:5/23/2013)... , May 23, 2013 Nephros, Inc. (OTC ... medical device company that develops and sells high performance ... its rights offering. In addition, the concurrent temporary reduction ... expired on May 17, 2013. Nephros estimates ... from the rights offering. A portion of the proceeds ...

Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9 Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2 Nephros Announces Completion of Rights Offering 2 Nephros Announces Completion of Rights Offering 3 Nephros Announces Completion of Rights Offering 4

[0] Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements [0] Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland [0] Nephros Announces Completion of Rights Offering

... 2010 New research from Lloydspharmacy reveals that whilst an ... sympathy levels at that time of the month appear to ... or fairly compassionate, a quarter of women (25%) who have ... unsympathetic. The survey shows that period pain ...

... Biotechnology Corporation ( www.generex.com ) (OTC Bulletin Board: ... date of its previously announced acquisition of a controlling interest ... 1, 2011. The Company also announced its receipt ... Listing and Hearing Review Council affirming the decision of the ...

Cached Medicine Technology:Lloydspharmacy Reveals Couples Beleaguered by Monthly Cramps 2 Generex Announces Extension of Global Medical Direct Acquisition Closing Date 2 Generex Announces Extension of Global Medical Direct Acquisition Closing Date 3

Lloydspharmacy Reveals Couples Beleaguered by Monthly Cramps Generex Announces Extension of Global Medical Direct Acquisition Closing Date

(Date:5/25/2013)... MA (PRWEB) May 25, 2013 Imagine running ... -- the energy loss, hot air and wasted energy! If ... house fan, a fireplace or clothes dryer, that may be ... Drafts from these often overlooked holes waste energy in the ... of heating and cooling loss in the home. , Drafts ...

(Date:5/25/2013)... 25, 2013 Dr. Leslie Gerstman ... FDA-approved to lift skin on the neck, on the brow ... practice, Medical Aesthetics. , Ultherapy is a non-surgical procedure for ... healing process to lift the skin over time. The use ... to see and then treat the deepest support layers of ...

(Date:5/25/2013)... 25, 2013 Communities of Distinction TV ... is the fifth largest media market in the United States ... one visitor destination in Texas and a major convention city. ... American West as it is home to many major museums. ... from sports to the arts. Residents and locals will be ...

(Date:5/25/2013)... and parasites that affect both dogs and humans, such ... can result in liver or kidney failure -- may ... These germs could be found in the ... Nelson, a clinical associate professor at Kansas State University,s ... be fatal, even with treatment," she said in a ...

(Date:5/25/2013)... May 25, 2013 Radius Engineering ... shelter company in the US and has been ... for over 35 years. M.E. and President, Walton ... of NBC Weapon Fundamentals and Shelter Engineering Standards, ... bible on shelter engineering. McCarthy is considered the ...

Breaking Medicine News(10 mins):Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 2 Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 3 Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 4 Health News:Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ 2 Health News:Communities of Distinction TV Presents May Air Dates for Dallas-Ft. Worth, Texas 2 Health News:Hidden Dangers Dog Dog Parks 2 Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 2 Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 3

[0] How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation [0] Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ [0] Communities of Distinction TV Presents May Air Dates for Dallas-Ft. Worth, Texas [0] Hidden Dangers Dog Dog Parks [0] Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster

... , PALM CITY, Fla., Aug. ... pleased to announce its decision to offer discount dental plans ... collaboration with DentalPlans.com, the leading online provider of discount dental ... offer Connectyx,s MedFlash(TM) product to its members. This collaboration is ...

... SHENZHEN, China, Aug. 27 /PRNewswire-Asia/ -- On August 10, 2009, ... the,"Company") entered into a contract with a machine producer in ... , This new machineries will constitute ... and operated in the Company,s,subsidiary in Huanggang, and it is ...

... Aug. 27 Mylan Inc. (Nasdaq: MYL ) ... to market 1% Clindamycin and 5% Benzoyl Peroxide Gel based ... subsidiary of Valeant Pharmaceuticals International. The preparation is the first ... the U.S. Food and Drug Administration (FDA). , ...

... , , DUBLIN, Ohio, Aug. 27 ... up to an aggregate purchase price of $1.2 billion of its ... is part of a previously announced plan to reduce the company,s ... Corp. and includes notes issued by both Cardinal Health and one ...

... , , NASHVILLE, ... (Nasdaq: CPIX ), a specialty pharmaceutical company focused on ... 2009 financial results. , , "Our second quarter ... events in the Company,s history--receipt of Food and Drug Administration (FDA) ...

... ST. PAUL, Minn., Aug. 27 The need for blood ... blood. From premature infants to an organ transplant recipient who will typically ... is urgent. , , We are currently ... can be given to save the life of anyone, from premature infants ...

Connectyx Technologies Offers MedFlash Members Access to 30+ Discount Dental Plans from DentalPlans.com Winner Medical Purchased New Purcotton Production Line to Meet Increasing Demand Mylan Begins Marketing First Generic Version of BenzaClin(R) Acne Treatment Cardinal Health Announces $1.2 Billion Debt Tender Offer Cumberland Pharmaceuticals Reports Second Quarter 2009 Financial Results Memorial Blood Centers in Urgent Need of Type O Negative and Type B Negative Blood Donors

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

Medicine Products:

Ketaject K1, Vitamin, Serum Itraconazole, Antifungal Serum Level, HPLC Isopropyl Alcohol